PE20211197A1 - Oligonucleotidos para modular la expresion de tmem106b - Google Patents
Oligonucleotidos para modular la expresion de tmem106bInfo
- Publication number
- PE20211197A1 PE20211197A1 PE2020001186A PE2020001186A PE20211197A1 PE 20211197 A1 PE20211197 A1 PE 20211197A1 PE 2020001186 A PE2020001186 A PE 2020001186A PE 2020001186 A PE2020001186 A PE 2020001186A PE 20211197 A1 PE20211197 A1 PE 20211197A1
- Authority
- PE
- Peru
- Prior art keywords
- oligonucleotide
- nucleotides
- tmem106b
- oligonucleotides
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UN OLIGONUCLEOTIDO ANTISENTIDO MONOCATENARIO DE 10 A 50 NUCLEOTIDOS DE LONGITUD, QUE COMPRENDE UNA SECUENCIA DE NUCLEOTIDOS CONTIGUOS DE 10 A 30 NUCLEOTIDOS DE LONGITUD QUE ES AL MENOS 90 % COMPLEMENTARIO DE UN ACIDO NUCLEICO DIANA DE LA PROTEINA TRANSMEMBRANA 106B DE MAMIFERO (TMEM106B); EN DONDE EL OLIGONUCLEOTIDO ES UN siARN O shARN O FORMA LA CADENA GUIA DE UN COMPLEJO DE siARN O shARN. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO OLIGONUCLEOTIDO QUE ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS COMO DEGENERACION LOBULAR FRONTOTEMPORAL (FTLD), ENFERMEDAD DE PARKINSON, LEUCODISTROFIAS HIPOMIELINIZANTES, ENFERMEDAD DE ALZHEIMER.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18156142 | 2018-02-09 | ||
US201862669251P | 2018-05-09 | 2018-05-09 | |
PCT/EP2019/053116 WO2019154979A1 (en) | 2018-02-09 | 2019-02-08 | Oligonucleotides for modulating tmem106b expression |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211197A1 true PE20211197A1 (es) | 2021-07-01 |
Family
ID=65433647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001186A PE20211197A1 (es) | 2018-02-09 | 2019-02-08 | Oligonucleotidos para modular la expresion de tmem106b |
Country Status (17)
Country | Link |
---|---|
US (1) | US11485975B2 (es) |
EP (1) | EP3749766A1 (es) |
JP (1) | JP7281474B2 (es) |
KR (1) | KR20200108315A (es) |
CN (1) | CN111868245A (es) |
AU (1) | AU2019219194A1 (es) |
BR (1) | BR112020016170A2 (es) |
CA (1) | CA3088071A1 (es) |
CL (1) | CL2020002038A1 (es) |
CR (1) | CR20200346A (es) |
IL (1) | IL276357A (es) |
MA (1) | MA51795A (es) |
MX (1) | MX2020008290A (es) |
PE (1) | PE20211197A1 (es) |
RU (1) | RU2020125769A (es) |
SG (1) | SG11202007093YA (es) |
WO (1) | WO2019154979A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4058152A4 (en) * | 2019-11-14 | 2024-05-08 | The Board of Regents of the University of Oklahoma | PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE |
JP2023527684A (ja) * | 2020-05-11 | 2023-06-30 | ジェネンテック, インコーポレイテッド | 神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法 |
WO2023141507A1 (en) * | 2022-01-20 | 2023-07-27 | Genentech, Inc. | Antisense oligonucleotides for modulating tmem106b expression |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
EP1414840A4 (en) | 2001-03-27 | 2005-04-13 | Univ Delaware | GENOMIC APPLICATIONS FOR MODIFIED OLIGONUCLEOTIDES |
EP2360251B1 (en) | 2001-07-12 | 2016-09-28 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
EP2141233B1 (en) | 2002-11-18 | 2016-10-19 | Roche Innovation Center Copenhagen A/S | Antisense design |
ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
CA2580504C (en) | 2004-09-17 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
ATE540118T1 (de) | 2006-10-18 | 2012-01-15 | Isis Pharmaceuticals Inc | Antisense-verbindungen |
EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
CN102325534B (zh) | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
LT2424991T (lt) | 2009-05-02 | 2018-09-25 | Genzyme Corporation | Neurodegeneracinių sutrikimų genų terapija |
WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
JP2013531981A (ja) | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
WO2012143379A1 (en) | 2011-04-20 | 2012-10-26 | Roche Glycart Ag | Method and constructs for the ph dependent passage of the blood-brain-barrier |
US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
AU2013262658A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating APOA1 and ABCA1 expression |
EA201492122A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии utrn |
EP2850184A4 (en) | 2012-05-16 | 2016-01-27 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION |
CN104884618A (zh) | 2012-11-15 | 2015-09-02 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸缀合物 |
WO2015113922A1 (en) | 2014-01-30 | 2015-08-06 | Roche Innovation Center Copenhagen A/S | Poly oligomer compound with biocleavable conjugates |
US20150231151A1 (en) | 2014-02-19 | 2015-08-20 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
CN104450621B (zh) * | 2014-09-30 | 2018-10-19 | 首都医科大学附属北京口腔医院 | Wdr63基因在间充质干细胞骨向和牙向分化过程中的调控方法 |
WO2016127002A1 (en) * | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
MX2017010066A (es) * | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
-
2019
- 2019-02-08 MA MA051795A patent/MA51795A/fr unknown
- 2019-02-08 CA CA3088071A patent/CA3088071A1/en not_active Abandoned
- 2019-02-08 MX MX2020008290A patent/MX2020008290A/es unknown
- 2019-02-08 RU RU2020125769A patent/RU2020125769A/ru not_active Application Discontinuation
- 2019-02-08 BR BR112020016170-5A patent/BR112020016170A2/pt not_active Application Discontinuation
- 2019-02-08 JP JP2020542377A patent/JP7281474B2/ja active Active
- 2019-02-08 PE PE2020001186A patent/PE20211197A1/es unknown
- 2019-02-08 SG SG11202007093YA patent/SG11202007093YA/en unknown
- 2019-02-08 EP EP19705306.9A patent/EP3749766A1/en active Pending
- 2019-02-08 AU AU2019219194A patent/AU2019219194A1/en not_active Abandoned
- 2019-02-08 CR CR20200346A patent/CR20200346A/es unknown
- 2019-02-08 CN CN201980020478.1A patent/CN111868245A/zh active Pending
- 2019-02-08 WO PCT/EP2019/053116 patent/WO2019154979A1/en unknown
- 2019-02-08 KR KR1020207022883A patent/KR20200108315A/ko not_active Application Discontinuation
-
2020
- 2020-07-28 IL IL276357A patent/IL276357A/en unknown
- 2020-08-05 CL CL2020002038A patent/CL2020002038A1/es unknown
- 2020-08-06 US US16/987,030 patent/US11485975B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2021514182A (ja) | 2021-06-10 |
RU2020125769A (ru) | 2022-03-10 |
BR112020016170A2 (pt) | 2020-12-15 |
MX2020008290A (es) | 2020-09-25 |
RU2020125769A3 (es) | 2022-03-10 |
KR20200108315A (ko) | 2020-09-17 |
MA51795A (fr) | 2020-12-16 |
AU2019219194A1 (en) | 2020-08-06 |
US20210054383A1 (en) | 2021-02-25 |
CL2020002038A1 (es) | 2020-10-23 |
IL276357A (en) | 2020-09-30 |
CA3088071A1 (en) | 2019-08-15 |
CN111868245A (zh) | 2020-10-30 |
JP7281474B2 (ja) | 2023-05-25 |
US11485975B2 (en) | 2022-11-01 |
SG11202007093YA (en) | 2020-08-28 |
WO2019154979A1 (en) | 2019-08-15 |
EP3749766A1 (en) | 2020-12-16 |
CR20200346A (es) | 2020-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123289T1 (el) | Ενωσεις ολιγονουκλεοτιδιων για τη στοχευση του huntingtin mrna | |
PE20171766A1 (es) | Oligomeros antisentido de tau y usos de estos | |
PE20211197A1 (es) | Oligonucleotidos para modular la expresion de tmem106b | |
BR112019005548A2 (pt) | tratamento da doença de huntington com aav | |
PE20180800A1 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
MX2020003965A (es) | Terapias genicas para los trastornos lisosomales. | |
EP4219713A3 (en) | Products and compositions | |
UY36126A (es) | ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?. | |
PE20191047A1 (es) | Compuestos y metodos para reducir de la expresion de atxn3 | |
EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
AR081993A1 (es) | TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA SUBUNIDAD a REGULADA POR VOLTAJE DEL CANAL DE SODIO (SCNA) POR INHIBICION DEL TRANSCRIPTO ANTISENTIDO NATURAL DE SCNA | |
SG10201903290YA (en) | Modified double-stranded rna agents | |
EA201790789A1 (ru) | Композиции и способы, предназначенные для ингибирования экспрессии гена hao1 (оксидазы 1 гидроксикислот (гликолат-оксидазы)) | |
MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
BR112016022742A2 (pt) | composições e métodos para modular a expressão de receptor de hormônio do crescimento | |
MX2014014902A (es) | Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. | |
ECSP10010637A (es) | Anticuerpos anti-factor d humanizados y sus usos | |
CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
PE20190626A1 (es) | Composiciones y metodos para modular la expresion del factor b del complemento | |
AR081420A1 (es) | Tratamiento de enfermedades relacionadas con el homologo 1 atonal (atoh1) mediante la inhibicion de la transcripcion antisentido natural para atoh1 | |
PE20181448A1 (es) | Composiciones y metodos para disminuir la expresion de tau | |
CL2018003044A1 (es) | 6-aminopiridina-3-yl tiazoles como moduladores de ror. | |
CL2017001042A1 (es) | Alcoholes trifluorometilo como moduladores de roryt | |
SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias |